Canadian speciality pharmaceutical company Paladin Labs has completed the acquisition of all outstanding common shares of Labopharm.

Labopharm develops novel polymeric, nano-delivery systems for delivery of water-insoluble and poorly bio-available drugs.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Paladin Labs interim president and CEO Mark Beaudet said that, through the addition of established international revenue streams, the acquisition will provide them the opportunity to build upon their existing operational capabilities.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact